IN8bio, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Co.'s lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). We show 13 historical shares outstanding datapoints in our INAB shares outstanding history coverage, used to compute INAB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing INAB market cap history over the course of time is important for investors
interested in comparing INAB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of INAB versus a peer is one thing; comparing
INAB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like INAB can fluctuate over the course of history.
With this page we aim to empower investors researching INAB by allowing them to research the INAB market cap history. |
Free INAB Email Alerts:
Video: The Importance of Market Cap
